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Abstract
Background High short-term failure rates have been
reported for several metal-on-metal hip resurfacing
(MoMHR) designs. Early observations suggested that
MoMHRs revised to total hip arthroplasties (THAs) for
pseudotumor had more major complications and inferior
patient-reported outcomes compared with other revision
indications. However, little is known about implant sur-
vivorship and patient-reported outcomes at more than 5
years after MoMHR revision.
Questions/purposes (1) What are the implant survivor-
ship, proportion of complications and abnormal
radiological findings, and patient-reported outcomes at a
median of 10 years after MoMHR revision surgery? (2) Are
survivorship, complications, and patient-reported outcomes
influenced by revision indication? (3) Do any other factors
predict survivorship, complications, and patient-reported
outcomes?
Methods Between 1999 and 2008, 53 MoMHR revision
procedures in 51 patients (mean age, 55 years; 62%
female) were performed at one center and were all included
in this retrospective study. Two patients (4%) were lost to
followup and two patients (4%) died before a minimum
followup of 7 years (median, 10.3 years; range 7–15 years).
Revision indications included pseudotumor (n = 16),
femoral neck fracture (n = 21), and other causes (n = 16).
In most cases (62%, n = 33) both components were revised
to a non-MoM bearing THA with the remainder (38%, n =
20: fracture, loosening, or head collapse) undergoing
femoral-only revision to a large-diameter MoM THA.
Postrevision complications, rerevision, Oxford Hip Score
(OHS), and UCLA score were determined using both a
longitudinally maintained institutional database and postal
questionnaire. Implant survivorship was assessed using the
Kaplan-Meier method (endpoint was rerevision surgery).
Radiographs at latest followup were systematically as-
sessed for any signs of failure (loosening, migration,
osteolysis) by one observer blinded to all clinical infor-
mation and not involved in the revision procedures.
Results Overall, 45% (24 of 53) experienced complica-
tions and 38% (20 of 53) underwent rerevision. Ten-year
survival free from rerevision for revised MoMHRs was
63% (95% confidence interval [CI], 48%–74%). Revision
indications were not associated with differences in the
frequency of complications or repeat revisions. With the
numbers available, 10-year survival free from rerevision
for pseudotumor revisions (56%; 95% CI, 30%–76%) was
not different from the fracture (68%; 95% CI, 42%–85%; p
= 0.359) and other groups (63%; 95% CI, 35%–81%; p =
0.478). Pseudotumor revisions had inferior OHSs (median,
21; range, 2–46; p = 0.007) and UCLA scores (median, 2;
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range, 2–7; p = 0.0184) compared with fracture and other
revisions. Ten-year survival free from rerevision after
femoral-only revision using another large-diameter MoM
bearing was lower (p = 0.0498) compared with all com-
ponent revisions using non-MoM bearings. After
controlling for potential confounding variables such as age,
sex, and revision indication, we found femoral-only revi-
sion as the only factor predicting rerevision (hazard ratio,
5.7; 95% CI, 1.1–29; p = 0.040).
Conclusions Poor implant survivorship and frequent
complications were observed at a median of 10 years after
MoMHR revision. However, patients undergoing femoral-
only revisions with large-diameter MoM bearings had the
worst survivorship, whereas patients revised for pseudo-
tumor had the most inferior patient-reported outcomes. Our
findings suggest these two patient subgroups require reg-
ular surveillance after MoMHR revision.
Level of Evidence Level III, therapeutic study.
Introduction
Frequent short-term failures have been observed with cer-
tain metal-on-metal hip resurfacing (MoMHR) designs
with registries reporting 10-year revision rates between
10% and 13% [2, 30, 34]. Failure of MoMHRs may arise
from traditional modes of arthroplasty failure (loosening,
infection, dislocation), complications unique to hip resur-
facing (femoral neck fracture and head collapse), and more
recently from articulation-related problems [5, 6, 10, 17,
21, 31]. Previous reports have shown that MoMHRs
revised for pseudotumor had an increased risk of major
complications and inferior patient-reported outcomes at a
mean 3-year followup compared with MoMHRs revised for
other indications and matched primary THAs [13]. In
addition to revision indication, other factors affecting
implant survivorship and patient-reported outcomes after
MoMHR revision are the type of revision performed and
the articulation used [9, 10, 19, 26]. Furthermore, the type
of revision performed and bearing used are interrelated
factors affecting implant survivorship given femoral-only
or acetabular-only revisions often result in large-diameter
MoM THAs or MoMHRs, which are both associated with
high failure rates [35, 36].
Many MoMHR designs were targeted for use specifi-
cally in young, active patients. Because many MoMHRs
have been implanted worldwide and the high failure rates
reported for several designs [16, 35], it is expected many
patients will require revision surgery in the future. How-
ever, little is known about the frequency of complications,
further surgery, and patient-reported outcomes more than 5
years postrevision [3, 14, 22, 26]. Furthermore, although
factors such as revision indication, type of revision per-
formed, and bearing surface have influenced short-term
implant survivorship and patient-reported outcomes, it is
unclear if these factors are important in predicting sur-
vivorship and patient-reported outcomes at extended
followup.
We therefore sought to determine the following: (1)
What are the implant survivorship, proportion of compli-
cations and abnormal radiological findings, and patient-
reported outcomes at a median of 10 years after MoMHR
revision surgery? (2) Are survivorship, complications, and
patient-reported outcomes influenced by revision indica-
tion? (3) Do any other factors predict survivorship,
complications, and patient-reported outcomes?
Patients and Methods
This retrospective study was undertaken at one specialist
arthroplasty center and is based on data from a longitudi-
nally maintained institutional database. All patients were
reviewed according to the institutional followup protocol;
therefore, institutional review board approval was not
required. All MoMHR revisions performed for any indi-
cation between December 1999 and March 2008 were
eligible for inclusion regardless of where the primary
MoMHR was performed.
Between December 1999 and March 2008, we per-
formed 6664 primary THAs and 1249 revision THAs (most
revisions were referred to our specialist unit). Of all pri-
mary THAs performed, 1308 (20%) were MoMHRs with
the Birmingham Hip Resurfacing (BHR; Smith & Nephew,
Warwick, UK; 48%, n = 633) representing the most com-
monly implanted MoMHR design. During this period, we
used MoMHR in young active male and female patients
with symptomatic hip arthritis. Of those who were treated
with MoMHR, 24 patients (2%) died with their implant
in situ, 167 (13%) MoMHRs were revised, and 37 (3%)
were lost to followup, whereas 910 patients (1080 hips
[82%]) were available for followup at a minimum of 2
years (median, 8.5 years; range, 2–16 years). We report on
all MoMHR revisions performed for any indication
between December 1999 and March 2008. These patients
have previously been reported on at a mean of 3 years after
MoMHR revision [13]. In addition to 49 MoMHR revisions
of our own patients, we performed revisions on four
patients referred from elsewhere. Of 51 patients (53
MoMHRs) undergoing revision, two patients (two hips
[4%]) died with their revision implant in situ, 20 patients
(20 hips [38%]) underwent rerevision, and two patients
(two hips [4%]) were lost to followup, whereas 27 patients
(29 hips [55%]) were available for followup at a minimum
of 7 years (median, 10.3 years; range, 7–15 years). These
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cases represent the first 53 MoMHR revisions performed at
this center and therefore include the surgeons’ learning
curves with revising these implants.
Mean age at revision was 55 years (SD, 11 years) and
62% (n = 33) were women (Table 1). The most commonly
revised implant was the BHR (55%, n = 29). Revisions
were performed at a mean of 1.6 years (SD, 2 years) from
the primary MoMHR by 13 surgeons. Revisions were
performed for pseudotumor (30%, n = 16), femoral neck
fracture (40%, n = 21), and other causes (30%, n = 16).
Other causes included aseptic loosening (n = 8), femoral
head collapse (n = 4), infection (n = 2), and recurrent
dislocation (n = 2). Most revisions were performed through
a posterior surgical approach (79%, n = 42; Table 1). In
62% (n = 33) of cases, both components were revised to a
non-MoM bearing. All femoral stems were cemented
(Exeter; Stryker, Newbury, UK; or CPT; Zimmer, Warsaw,
IN, USA) and all acetabular components were uncemented
(Trident [Stryker] or Trilogy [Zimmer]).
In the remaining 38% (n = 20), only the femoral com-
ponent was revised (typically for fracture, loosening, or
head collapse) because the acetabular component was in an
acceptable position intraoperatively and therefore retained.
These 20 hips underwent femoral-only component revi-
sions using either an uncemented (numerous different
designs) or cemented stem (CPT) with large-diameter
MoM bearings matching the inner diameter of the retained
acetabular components. These revisions were performed
pre-2008, before complications with large-diameter MoM
THA bearings were known [35, 36].
All patients received antibiotic prophylaxis and throm-
boprophylaxis perioperatively and postoperatively
according to the institution’s protocol at the time. Postop-
erative weightbearing was dependent on the reconstruction
performed. Most patients were allowed to immediately
bear full weight with walking aids as required. Up to 6
weeks of partial or nonweightbearing were recommended
if concerns existed about the initial stability of the recon-
struction and/or soft tissues after pseudotumor
de´bridement. All patients received standard advice on
antidislocation precautions for the first 6 weeks after
revision (eg, sleep on back, avoid low chairs).
After revision, patients were reviewed in the clinic at
6 weeks and 1 year postoperatively. Thereafter review
was according to clinical need, usually annually. Con-
sultations included clinical examination, radiographs
(AP pelvis and lateral hip), and completion of the Oxford
Hip Score (OHS) questionnaire [7] and UCLA activity
score questionnaire [1]. Patients with pain after revision
underwent further investigation, including blood tests (to
assess for infection and MoM bearing wear), cross-sec-
tional imaging, and, where indicated, joint aspiration.
From 2012 all patients with large-diameter MoM THAs
underwent regular followup with blood metal ions and
cross-sectional imaging as recommended by national
authorities [28].
Study endpoints of interest after MoMHR revision were
(1) complications related to surgery; (2) rerevision surgery;
(3) OHS; (4) UCLA score; and (5) radiological abnor-
malities. One observer (GSM) searched the hospital’s
clinical databases for all revised MoMHRs. Details of
further surgery were recorded, including indication, surgi-
cal findings, and components exchanged. If further surgery
was performed elsewhere, the respective hospital was
contacted to complete data collection. Deaths were inves-
tigated using patient notes and information held by the
general practitioner to determine whether deaths were
related to surgery and whether rerevision occurred before
death.
All surviving patients not undergoing rerevision
received a postal questionnaire with nonresponders con-
tacted by telephone (27 of 29 patients responded to the
questionnaire [93%]). The questionnaire requested details
of complications since revision, including further surgery.
Patients also completed the OHS (0 = worst outcome and
48 = best outcome) [7, 29] and the UCLA activity score
(1 = wholly inactive and 10 = regular participation in
impact sports) [1]. All postrevision radiographs were as-
sessed for evidence of component loosening, migration, or
osteolysis [8, 11, 15] by one observer (GSM) blinded to all
clinical information.
Statistical Analysis
All statistical analysis was performed using Stata Version
13.1 (College Station, TX, USA). Either the median and
range or the mean and SD were reported depending on data
distribution. Survival analysis for revised MoMHRs was
performed using the Kaplan-Meier method with rerevision
surgery (removal or exchange of any component) used as
the endpoint. Patients not undergoing further surgery were
censored at latest followup (clinic review, questionnaire
completion, or death).
The proportion of patients experiencing complications
or undergoing rerevision was compared between different
revision indications (pseudotumor, fracture, other) using a
chi-square test with Yates’ correction. Differences in
postrevision OHS and UCLA scores between revision
indications were analyzed using the Kruskal-Wallis test.
Cox proportional hazards models (univariate and multi-
variate) were used to assess the association of predictor
variables (age, gender, body mass index, revision indica-
tion, type of revision performed, and bearing used) on time
to rerevision. The proportional hazards assumption was
assessed using Schoenfeld’s residuals. The significance
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level was set at p\ 0.05 with confidence intervals (CIs)
also at the 95% level.
Results
Overall, 45% (n = 24) of patients undergoing MoMHR
revision surgery experienced complications and 38% (n =
20) underwent rerevision surgery. Rerevisions were per-
formed at a mean 3 years (SD, 3 years) and were most
commonly for pseudotumor (40%; n = 8), recurrent dislo-
cation (20%; n = 4), and deep infection (20%; n = 4)
(Table 2). Two patients (two hips) died at 6 years and 13
years after revision with no hip rerevised before death.
Ten-year survival free from rerevision for all revised
MoMHRs was 63% (95% CI, 48%–74%; Fig. 1). Median
OHS and UCLA scores for surviving patients were 38
(range, 2–48) and 6 (range, 2–10), respectively. One sur-
viving hip had evidence of radiological failure
(stable nonprogressive radiolucency femoral Zone 1).
Complications not resulting in rerevision included femoral
nerve palsy (n = 3; two permanent and one resolved) and
one case of symptomatic intermittent claudication caused
by pseudotumor stenosis of the external iliac artery (re-
quired angioplasty and stenting).
The proportion of complications after pseudotumor
revision (69% [11 of 16]) was no different with the num-
bers available compared with the fracture group (33%
[seven of 21]) and the other group (38% [six of 16]) (chi-
square test; p = 0.076; Table 3). The proportion of rere-
visions after pseudotumor revision (44% [seven of 16]) was
no different with the numbers available compared with the
Table 1. Summary of 53 metal-on-metal hip resurfacings undergoing revision surgery
Patient and revision surgical factors Details 53 hips (51 patients)
Sex Male 20 (38%)
Female 33 (62%)
Age at revision Mean (range) in years 55.4 (23–71)
SD 10.8
Body mass index at revision Mean (range) in kg/m2 28.2 (19–39)
SD 4.7
Bilateral metal-on-metal hips Total patients 2 (4 hips)
Time to revision from hip resurfacing Mean (range) in years 1.6 (0.01–7)
SD 1.8
Resurfacing implant revised Birmingham Hip Resurfacing (Smith & Nephew, Warwick, UK) 29 (55%)
Conserve (Wright Medical Technology, Memphis, TN, USA) 21 (40%)
Cormet (Corin, Cirencester, UK) 3 (6%)
Revision indication Femoral neck fracture 21 (40%)
Pseudotumor 16 (30%)
Other 16 (30%)
Revision approach Posterior 42 (79%)
Anterolateral 8 (15%)
Smith-Petersen 3 (6%)
Components revised Both components 33 (62%)
Femoral only* 20 (38%)
Stem fixation Cemented 48 (91%)
Uncemented 5 (9%)
Revision femoral head diameter Mean (range) in millimeters 38 (28–54)
SD 8.5
Revision bearing Metal-on-metal* 20 (38%)
Metal-on-polyethylene 18 (34%)
Ceramic-on-ceramic 10 (19%)
Ceramic-on-polyethylene 5 (9%)
* All cases undergoing femoral-only component revision were revised to stemmed large-diameter metal-on-metal THAs; all acetabular fixation
was uncemented.
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fracture group (33% [seven of 21]) and the other group
(38% [six of 16]) (chi-square test; p = 0.811; Table 3).
Ten-year survival free from rerevision after pseudotumor
revision (56%; 95% CI, 30%–76%) was no different with
the numbers available compared with that after revision for
fracture (68%; 95% CI, 42%–85%; p = 0.359) and other
indications (63%; 95% CI, 35%–81%; p = 0.478; Fig. 2).
Patients undergoing pseudotumor revision had inferior
OHSs (median, 21; range, 2–46; Kruskal-Wallis test; p =
0.007; Fig. 3) compared with patients revised for fracture
(median, 44; range, 14–48) and other indications (median,
45; range, 27–48). Patients undergoing pseudotumor revi-
sions had inferior UCLA scores (median, 2; range, 2–7;
Kruskal-Wallis test; p = 0.0184; Fig. 4) compared with
revisions for fracture (median, 7; range, 3–9) and other
indications (median, 6; range, 2–10).
The proportion of rerevisions after femoral-only revi-
sion using another large-diameter MoM bearing (55% [11
of 20]) was higher compared with all component revisions
using non-MoM bearings (27% [nine of 33]) (relative risk,
3.3; 95% CI, 1.2–8.9; p = 0.044). Ten-year survival free
from rerevision after femoral-only revisions (38%; 95% CI,
16%–60%) was lower (p = 0.0498) compared with all
component revisions (76%; 95% CI, 57%–87%; Fig. 5).
After controlling for potential confounding variables such
as age, sex, body mass index, and revision indication, we
found that femoral-only revision was the only factor
associated with an increased rerevision rate (hazard ratio,
5.7; 95% CI, 1.1–29; p = 0.040; Table 4). Of the 11 rere-
visions performed after femoral-only revisions, 64% (n =
7) were for pseudotumor with the remainder performed for
deep infection (27%, n = 3) and periprosthetic fracture
(9%, n = 1). In hips not undergoing rerevision, there was no
difference with the numbers available between the OHS
(median, 41; range, 14–48 versus median, 37; range, 2–48;
Wilcoxon rank-sum test p = 0.798) and UCLA score
(median, 6; range, 3–9 versus median, 5.5; range, 2–10;
Wilcoxon rank-sum test p = 0.425) in femoral-only revi-
sions compared with all component revisions.
Discussion
Several MoMHR designs have experienced high short-
term failure rates [35]. Studies reporting early implant
survivorship and patient-reported outcomes after MoMHR
revision observed inferior results after pseudotumor
revisions [13, 26], single-component revisions [9, 10], and
when using another MoM bearing [19, 26]. However,
little is known about these endpoints more than 5 years
after MoMHR revision. Because of high MoMHR failure
rates and the young age of patients with these failed
implants compared with patients undergoing THA revi-
sion [25, 32], it is important to establish long-term
implant survivorship and patient-reported outcomes after
revision so patients can be appropriately counseled about
the results and potential risks of further intervention. This
is the first study reporting on implant survivorship, the
proportion of complications and abnormal radiological
findings, and patient-reported outcomes at a median of 10
years after MoMHR revision. Although poor implant
survivorship and frequent complications were observed
after revision for all indications, pseudotumor revisions
had inferior patient-reported outcomes compared with
other revision indications. Furthermore, patients under-
going femoral-only revisions using large-diameter MoM
bearings had the worst implant survivorship. These two
patient subgroups therefore require regular followup after
MoMHR revision.
We recognize limitations for our study. First, although
our cohort size is similar to previous studies [9, 26, 37],
some subgroup analyses may have been affected by small
numbers. However, given the limited long-term data
reported after MoMHR revision, we consider our findings
important and recommend these can be used until larger
studies become available. Second, we could not determine
the latest implant status and patient-reported outcomes in
two hips (censored between 2 and 6 years postrevision).
These patients may have undergone rerevision elsewhere
or may have unsatisfactory patient-reported outcomes,
which would affect our findings. Third, this study includes
the surgeons’ learning curves with revising MoMHRs. This
may have adversely affected the reported findings, because
increasing experience improves implant survivorship and
patient-reported outcomes after MoMHR revision [9].
Fig. 1 A Kaplan-Meier survival analysis illustrating the all-cause
rerevision rate for 53 revised hip resurfacings at 10 years. The shaded
area represents the upper and lower limits of the 95% CIs with the
number of hips at risk detailed below the x-axis. The 10-year survival
free from rerevision for revised hip resurfacings was 63% (95% CI,
48%–74%).
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Finally, our findings may not apply after revision of MoM
THAs or MoMHR designs not assessed here.
Almost half of the patients undergoing MoMHR revi-
sion subsequently experienced major complications with
over one-third undergoing rerevision. Early studies
reported short-term survivorship and patient-reported out-
comes after MoMHR revision for most indications were
comparable to conventional THA [3, 13, 22]. Our findings
suggest this is not true at long-term followup. Although our
surviving MoMHR revisions have OHSs (median, 38)
similar to those reported 10 years after primary THA
(median, 41) [23], the 10-year survival free from rerevision
for revised MoMHRs (63%) was considerably lower
compared with primary THA (96%–98%) [30]. Perhaps
more concerning is that 10-year survival free from rerevi-
sion for revised MoMHRs is lower than that for the
recalled Articular Surface Replacement (DePuy, Warsaw,
IN, USA) MoMHR device (72%; 95% CI, 70%–74%) [27,
28, 30]. This illustrates how poor the long-term results of
MoMHR revision can be. It is important for surgeons to
appreciate this poor implant survivorship and for young
MoMHR patients potentially undergoing further surgery to
be made aware of this. Importantly, all operations were
performed by experienced revision surgeons previously
reporting 10-year survival free from rerevision of 82%
(95% CI, 80%–85%) after 1176 revision THAs [32].
Table 3. Summary of complications and re-revisions by initial revision indication
Study outcome of interest
after revision surgery
Whole cohort
(n = 53)
Fracture group
(n = 21)
Pseudotumor group
(n = 16)
Other group
(n = 16)
All complications 45% (n = 24) 33% (n = 7) 69% (n = 11) 38% (n = 6)
Complications not requiring
rerevision surgery
8% (n = 4) 0% (n = 0) 25% (n = 4)
3 Femoral nerve palsy
1 Intermittent claudication resulting from
stenosis of external iliac artery
0% (n = 0)
Complications requiring
rerevision surgery
38% (n = 20) 33% (n = 7)
3 Pseudotumor
3 Deep infection
1 Periprosthetic fracture
44% (n = 7)
4 Recurrent dislocation
2 Acetabular component loosening
1 Pseudotumor recurrence with dislocation
38% (n = 6)
4 Pseudotumor
1 Deep infection
1 Periprosthetic fracture
Fig. 2 A Kaplan-Meier survival analysis illustrating the all-cause
rerevision rate for 53 revised hip resurfacings at 10 years by initial
revision indication. The CIs have not been included for clarity.
Univariate analysis demonstrated 10-year survival free from rerevi-
sion after pseudotumor revision (56%; 95% CI, 30%–76%) was not
different from the 10-year survival free from rerevision after revision
for fracture (68%; 95% CI, 42%–85%; p = 0.359) and other
indications (63%; 95% CI, 35%–81%; p = 0.478). This finding was
confirmed in the multivariate model.
Fig. 3 A box and whisker plot of the OHS after revision hip
resurfacing by initial revision indication is shown. The horizontal line
within the box is the median. The two ends of each box represent the
25th and 75th percentiles and the difference between these values is
the interquartile range (IQR). The whiskers extending from the box
represent the most extreme data points, which are no more than 1.5
times the IQR from the 75th percentile (upper whisker) and no less
than 1.5 times the IQR from the 25th percentile (lower whisker).
Values lying outside of the whiskers represent outliers.
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Therefore, although there may be a learning curve for revising
MoMHRs, our findings suggest these revisions must not be
underestimated and considered ‘‘simple’’ revisions, even for
experienced arthroplasty surgeons. These poor results raise the
question of whether surgeons should consider early revision
with some evidence suggesting this improves short-term sur-
vivorship and patient-reported outcomes [9].
An earlier report on this cohort observed pseudotumor
revisions had a higher proportion of complications and
inferior patient-reported outcomes compared with
MoMHRs revised for other indications [13]. More recently
Su and Su [37] reported inferior patient-reported outcomes
in MoMHRs revised for unexplained pain compared with
other indications. The present study observed no difference
in the proportion of complications or implant survivorship
in MoMHRs revised for pseudotumor compared with other
indications. We suspect this variance with our earlier report
[13] relates to followup length. All pseudotumor revisions
undergoing rerevision occurred within 3 years of initial
revision (Fig. 2) when the survival free from rerevision of
nonpseudotumor revisions was acceptable. The poor initial
survivorship and patient-reported outcomes after pseudo-
tumor revision are likely related to intervening at a late
stage because at the time the destructive nature of pseu-
dotumors was not appreciated [13, 31]. Between 3 and 10
years after initial revision, a number of the fracture and
other MoMHR revisions underwent rerevision (Table 2).
Most rerevisions in the fracture and other groups were also
for pseudotumor because these patients were initially
revised to large-diameter MoM THAs at a time when the
high failure rates of such devices were unknown [36].
Therefore, we suspect that MoMHR revisions for
nonpseudotumor indications (fracture, loosening, head
collapse) would have achieved better survivorship and/or
patient-reported outcomes than those reported if they were
not initially revised to another large-diameter MoM bearing.
By contrast, our observations that patient-reported outcomes
were inferior in surviving pseudotumor revisions compared
with MoMHR revisions for other indications support short-
term reports [13, 26, 37]. Although the patient-reported
outcomes at a median of 10 years after MoMHR revision for
fracture and other indications are comparable to primary
THA [23], patient-reported outcomes after pseudotumor
revision remained poor. The poor patient-reported outcome
after pseudotumor revision is again related to our late
recognition of these first 16 pseudotumors, which can rep-
resent a destructive complication [13, 19, 31]. In all 16
pseudotumor revisions, there was some degree of macro-
scopic damage to the gluteus medius muscle with or without
associated bone loss with three cases also having more
extensive damage of the surrounding soft tissues, which
required reconstructive input from a plastic surgeon at
revision. Furthermore, de´bridement of affected peripros-
thetic tissues can adversely affect hip stability and patient-
reported outcomes [24]. Although our pseudotumor revi-
sions were performed when this complication was not
understood, increased awareness has resulted in improved
patient-reported outcomes after pseudotumor revision at this
center [20] and elsewhere [9].
Femoral-only revision with large-diameter MoM bear-
ings was the only predictor of rerevision. Even when
revision indication was controlled for, these patients had an
increased rerevision risk (hazard ratio, 5.7) compared with
all component revisions using non-MoM articulations. The
poor implant survivorship after femoral-only revisions was
mainly the result of pseudotumor formation. All femoral-
only revisions were performed in MoMHRs initially
revised for fracture or other reasons; therefore, no
Fig. 4 A box and whisker plot of the UCLA activity score after
revision hip resurfacing by initial revision indication is shown.
Fig. 5 A Kaplan-Meier survival analysis illustrating the all-cause
rerevision rate for 53 revised hip resurfacings at 10 years by type of
revision performed. The CIs have not been included for clarity.
Univariate analysis demonstrated 10-year survival free from rerevi-
sion after femoral-only revisions with another large-diameter MoM
bearing (38%; 95% CI, 16%–60%) was lower (p = 0.0498) compared
with all component revisions (76%; 95% CI, 57%–87%). This finding
was confirmed in the multivariate model.
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pseudotumors were present at the first revision procedure.
Most rerevisions in this subgroup were performed for new
pseudotumors, which developed after implantation of the
second large-diameter MoM bearing. Our findings support
earlier observations that single-component MoMHR revisions
to another MoM bearing result in inferior survivorship and
patient-reported outcomes compared with all component
revisions using non-MoM articulations [9, 10, 19]. These poor
results are related to the use of large-diameter MoM THAs as
the revision implant with high failure rates reported for these
devices [4, 16, 36], resulting from pseudotumor formation
because of wear and corrosion at the stem taper and femoral
head interface as well as at the bearing surface [18]. Our
revisions were performed before recognition of this problem.
Although most regulatory authorities recommend regular
followup of large-diameter MoM THAs regardless of symp-
toms [12, 28, 38], it is important not to overlook patients who
currently have these implants in situ after early single-com-
ponent MoMHR revisions. Our observations suggest this
subgroup requires regular surveillance as a result of the
increased risk of developing pseudotumors within 10 years of
revision. In light of our findings, it is now our preference to
revise both MoMHR components and implant a non-MoM
THA when dealing with failed MoMHRs. This has been
suggested previously [19, 26], and using this approach in a
subgroup of our patients produced a more acceptable 10-year
survival rate free from rerevision of 76% after revision
MoMHR. However, we acknowledge that other surgical
options exist. Recently some surgeons have elected to retain
well-fixed and adequately positioned acetabular components
when revising failed MoMHRs. These procedures involve
single-component revisions using dual-mobility metal-on-
polyethylene articulations or a polyethylene liner cemented
into the retained MoMHR shell with good subsequent implant
survivorship and patient-reported outcomes observed [33].
Although this may become a more acceptable approach for
failed MoMHRs in the future, it must be recognized that only
short-term results have been reported and that the use of such
techniques is currently off-label [33].
Poor implant survivorship and frequent complications
were observed at a median of 10 years after MoMHR
revision surgery performed for all indications. However,
patients undergoing femoral-only revisions with large-di-
ameter MoM THA bearings had the worst survivorship
with these patients almost six times more likely to undergo
rerevision compared with all component revisions using
non-MoM bearings. Furthermore, patients revised for
pseudotumor had inferior patient-reported outcomes com-
pared with MoMHRs revised for other indications. We
therefore recommend these two patient subgroups undergo
regular clinical surveillance (typically annually) in line
with previously published followup protocols [12, 38].
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